During incubation (25 min) with a tetramethylbenzidine answer, the solution stains in the wells contained the formed antigenCIgG-conjugate complexes

During incubation (25 min) with a tetramethylbenzidine answer, the solution stains in the wells contained the formed antigenCIgG-conjugate complexes. 28 September and 30 December 2020. Blood samples were tested by enzyme-linked immunosorbent assay D-5501 SARS-Cov-2-IgG-EIA-BEST and D-5502 SARS-Cov-2-IgM-EIA-BEST (AO Vector-Best, Novosibirsk, Russia). The overall seropositivity rate was 28.33C28.53%. SARS-CoV-2 antibodies were detected in 17.23% (adjusted prevalence of 17.17C17.29%) of participants in the high-risk and 45.95% (adjusted prevalence of 45.91C46.24%) in the symptomatic group. Higher IgG and IgM titers were observed in women compared to men, as well as in participants in the symptomatic group compared to those in the high-risk group. The results indicate that the seroprevalence among residents in several Russian regions is low (28.38%) and inadequate to provide herd immunity. The lower seroprevalence among participants in the high-risk group may be attributed to the enforcement of healthcare protocols and the use of adequate personal protective equipment. Keywords: antibody, COVID-19, focus groups, global health, high-risk groups, seroprevalence 1. Introduction The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly to more than 180 countries worldwide, resulting in high levels of morbidity and mortality. As of 9 May 2021, nearly 166 million COVID-19 cases and 3449 million deaths have been reported [1]. The clinical manifestations of COVID-19 can range from an asymptomatic/mild disease to severe disease with acute respiratory tract infections. Data from Aspartame the meta-analysis suggest that the pooled prevalence of asymptomatic COVID-19 is about 48% and is higher in females than in males [2]. With that, because of the absence of symptoms and complaints, asymptomatic COVID-19 carriers can escape detection from the health system and, thus, are challenging for the implementation of preventive measures and infection control [2]. Thus, as the majority of currently available data are restricted to symptomatic patients with laboratory-confirmed COVID-19, the extent of the pandemic may be underestimated, and the virus may have a great potential for Aspartame silent spread through the population [3,4]. Moreover, a recent meta-analysis reported a pooled ratio of serologically-detected infections to virologically-confirmed cases of 7.7; that is, Aspartame for each confirmed case of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, at least six infections remain undetected by current surveillance systems [5]. While CDC does not recommend serology testing to diagnose the current infection [6], its utility and importance for public health should be more emphasized in the COVID-19 pandemic [7]. As the duration of immunity to SARS-CoV-2 dictates the overall course of the pandemic and can also affect post-pandemic dynamics [8], serological studies are urgently needed [9]. The results Aspartame of such studies can facilitate the assessment of infection spread, infection fatality rates, level of herd immunity, and the impact of interventions [5]. Public health decision-making would especially benefit from data pertaining to seroprevalence among individuals in occupations with a high risk of exposure to SARS-CoV-2 due to frequent social interactions (e.g., service-sector employees) [10]. The seroconversion of specific SARS-CoV-2 IgG/IgM antibodies can start as early as 4 days [11], with the median time of 7C8 days [12], after the onset Aspartame of illness, and both IgG and IgM titers plateau within 6 days after seroconversion [13]. Most patients have neutralizing titers on days 14C20 with great titer variability [14]. The duration of the positivity rate exceeding 80% is about seven weeks for IgM and about 3C6 months for IgG [15]. According to the current data, the prevalence and dynamic characteristics of SARS-CoV-2 IgG/IgM antibodies are affected by age, sex, and disease Rabbit Polyclonal to ITGA5 (L chain, Cleaved-Glu895) severity [16]; however, the research population studied is still not comprehensive and that causes the discrepancies in results among the studies [14]. A considerable amount of literature has been published on the impact of the pandemic on healthcare workers [17], while the studies investigating other essential workers with direct customer exposure are limited [18,19]. With that, the elevated risk of infection was not limited to healthcare workers, and other high-risk occupations being affected during the pandemic comprised almost half of local transmission and the majority of the possible work-related cases [10,20,21]. Although the COVID-19 outbreak in Russia started later compared to many neighboring European countries, Russia is currently among the six countries with the highest number of confirmed COVID-19 cases, as of 9 May 2021 [22,23]. Limited data suggest that the seroprevalence of SARS-CoV-2 infection in Russia was approximately 9C10% in MayCJune 2020 [24], reaching 19.6C31.3% [25,26,27] by the end of the year. At present, there are no data for seropositivity rates in specific cohorts, such as those with a high risk of occupational exposure to SARS-CoV-2. Moreover, because of the high risk for infection spread by persons with an asymptomatic form of the disease, serological studies should include those from high-risk groups even without the symptoms. Thus, the present pilot study aimed to assess and compare antibody seropositivity prevalence rates among symptomatic individuals and individuals in occupations with a high risk of exposure to SARS-CoV-2. 2. Materials and Methods 2.1. Location of the Study.